Author(s): Burel SA, Machemer T, Ragone FL, Kato H, Cauntay P, et al.
Antisense oligonucleotides (ASO) containing 2′-O-methoxyethyl ribose (2′-MOE) modifications have been shown to possess both excellent pharmacokinetic properties and robust pharmacological activity in several animal models of human disease. 2′-MOE ASOs are generally well tolerated, displaying minimal to mild proinflammatory effect at doses far exceeding therapeutic doses. Although the vast majority of 2′-MOE ASOs are safe and well tolerated, a small subset of ASOs inducing acute inflammation in mice has been identified. The mechanism for these findings is not clear at this point, but the effects are clearly sequence-specific. One of those ASOs, ISIS 147420, causes a severe inflammatory response atypical of this class of oligonucleotides characterized by induction in interferon-β (IFN-β) at 48 h followed by acute transaminitis and extensive hepatocyte apoptosis and necrosis at 72 h. A large number of interferon-stimulated genes were significantly up-regulated in liver as early as 24 h. We speculated that a specific sequence motif might cause ISIS 147420 to be mistaken for viral RNA or DNA, thus triggering an acute innate immune response. ISIS 147420 toxicity was independent of Toll-like receptors, because there was no decrease in IFN-β in Toll/interleukin-1 receptor-domain-containing adapter-inducing IFN-β or Myd88-deficient mice. The involvement of cytosolic retinoic acid-inducible gene (RIG)-I-like pattern recognition receptors was also investigated. Pretreatment of mice with melanoma differentiation-associated gene 5 (MDA5) and IFN-β promoter stimulator-1 ASOs, but not RIG-I or laboratory of genetics and physiology 2 (LGP2) ASOs, prevented the increase in IFN-β and alanine aminotransferase induced by ISIS 147420. These results revealed a novel mechanism of oligonucleotide-mediated toxicity requiring both MDA5 and IPS-1 and resulting in the activation of the innate immune response.
Referred From: https://dx.doi.org/10.1124/jpet.112.193789
Author(s): Chin KL, Anis FZ, Sarmiento ME, Norazmi MN, Acosta A, et al.
Author(s): Negishi H, Taniguchi T, Yanai H
Author(s): Di Franco S, Turdo A, Todaro M, Stassi G
Author(s): Bessis N, GarciaCozar FJ, Boissier MC
Author(s): Sakurai H, Kawabata K, Sakurai F, Nakagawa S, Mizuguchi H, et al.
Author(s): Lennox KA, Behlke MA
Author(s): Leeds JM, Henry SP, Geary R, Burckin T, Levin AA, et al.
Author(s): Behlke MA
Author(s): Jacobi AM, Rettig GR, Turk R, Collingwood MA, Zeiner SA, et al.
Author(s): Neun BW, Dobrovolskaia MA
Author(s): Neun BW, Dobrovolskaia MA
Author(s): Potter TM, Neun BW, Rodriguez JC, Ilinskaya AN, Dobrovolskaia MA, et al.
Author(s): Fennrich S, Hennig U, Toliashvili L, Schlensak C, Wendel HP, et al.
Author(s): Coch C, Luck C, Schwickart A, Putschli B, Renn M, et al.
Author(s): Daneshian M, Von Aulock S, Hartung T
Author(s): Dobrovolskaia MA
Author(s): Hasiwa N, Daneshian M, Bruegger P, Fennrich S, Hochadel A, et al.
Author(s): Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, et al.
Author(s): Vessillier S, Eastwood D, Fox B, Sathish J, Sethu S, et al.
Author(s): Alvarez-Salas LM
Author(s): Henry SP, Geary RS, Yu R, Levin AA
Author(s): Holmlund JT, Monia BP, Kwoh TJ, Dorr FA
Author(s): Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, et al.
Author(s): Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA
Author(s): Keefe AD, Pai S, Ellington A
Author(s): Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, et al.